International Journal of Clinical Oncology

, Volume 11, Issue 2, pp 90–107 | Cite as

Current status and perspective of antiangiogenic therapy for cancer: urinary cancer

  • Shigeru Kanda
  • Yasuyoshi Miyata
  • Hiroshi Kanetake
REVIEW ARTICLE

Abstract

Angiogenesis is considered a prerequisite for solid tumor growth. Antiangiogenic therapy reduces tumor size and extends host survival in a number of preclinical animal models. However, in humans antiangiogenic therapy is a poor promoter of tumor regression and has shown minimal effect on patient survival. In urinary cancers, such as renal cell cancer, prostate cancer, and bladder cancer, advanced refractory disease is a good candidate for antiangiogenic therapy because of its resistance to ordinary chemotherapy, radiotherapy, and hormonal therapy. Unique characteristics of molecular mechanisms underlie the induction of angiogenesis in urinary cancers. In this review, we summarize these unique mechanisms and review the results of clinical trials of antiangiogenic therapy for these cancers, discussing prospects and problems relating to antiangiogenic therapy.

Key words

VEGF FGF Thymidine phosphorylase p53 Angiogenesis Urological cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Folkman, J 1990What is the evidence that tumors are angiogenesis dependent?J Natl Cancer Inst8246PubMedGoogle Scholar
  2. 2.
    Carmeliet, P, Jain, RK 2000Angiogenesis in cancer and other diseasesNature (Lond)407249257Google Scholar
  3. 3.
    Bikfalvi, A, Bicknell, R 2002Recent advances in angiogenesis, anti-angiogenesis and vascular targetingTrends Pharmacol Sci23576582CrossRefPubMedGoogle Scholar
  4. 4.
    Hicklin, DJ, Ellis, LM 2005Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesisJ Clin Oncol2310111027PubMedGoogle Scholar
  5. 5.
    Mydlo, JH, Heston, WD, Fair, WR 1988Characterization of a heparin-binding growth factor from adenocarcinoma of the kidneyJ Urol14015751579PubMedGoogle Scholar
  6. 6.
    Kanda, S, Hisamatsu, H, Igawa, T,  et al. 1993Peritubular endothelial cell proliferation in mice during compensatory renal growth after unilateral nephrectomyAm J Physiol265F712716PubMedGoogle Scholar
  7. 7.
    Eguchi, J, Nomata, K, Kanda, S,  et al. 1992Gene expression and immunohistochemical localization of basic fibroblast growth factor in renal cell carcinomaBiochem Biophys Res Commun183937944CrossRefPubMedGoogle Scholar
  8. 8.
    Emoto, N, Isozaki, O, Ohmura, E,  et al. 1994Basic fibroblast growth factor (FGF-2) in renal cell carcinoma, which is indistinguishable from that in normal kidney, is involved in renal cell carcinoma growthJ Urol15216261631PubMedGoogle Scholar
  9. 9.
    Brown, LF, Berse, B, Jackman, RW,  et al. 1993Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomasAm J Pathol14312551262PubMedGoogle Scholar
  10. 10.
    Takahashi, A, Sasaki, H, Kim, SJ,  et al. 1994Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesisCancer Res5442334237PubMedGoogle Scholar
  11. 11.
    Ferrara, N 2004Vascular endothelial growth factor: basic science and clinical progressEndocr Rev25581611CrossRefPubMedGoogle Scholar
  12. 12.
    Keyt, BA, Berleau, LT, Nguyen, HV,  et al. 1996The carboxyl-terminal domain (111–165) of vascular endothelial growth factor is critical for its mitogenic potencyJ Biol Chem27177887795PubMedGoogle Scholar
  13. 13.
    Houck, KA, Leung, DW, Rowland, AM,  et al. 1992Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanismsJ Biol Chem2672603126037PubMedGoogle Scholar
  14. 14.
    Park, JE, Keller, GA, Ferrara, N 1993The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGFMol Biol Cell413171326PubMedGoogle Scholar
  15. 15.
    Plouet, J, Moro, F, Bertagnolli, S,  et al. 1997Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effectJ Biol Chem2721339013396CrossRefPubMedGoogle Scholar
  16. 16.
    Thelen, P, Hemmerlein, B, Kugler, A,  et al. 1999Quantification by competitive quantitative RT-PCR of VEGF121 and VEGF165 in renal cell carcinomaAnticancer Res1915631565PubMedGoogle Scholar
  17. 17.
    Tomisawa, M, Tokunaga, T, Oshika, Y,  et al. 1999Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinomaEur J Cancer35133137CrossRefPubMedGoogle Scholar
  18. 18.
    Gnarra, JR, Tory, K, Weng, Y,  et al. 1994Mutations of the VHL tumour suppressor gene in renal carcinomaNat Genet78590CrossRefPubMedGoogle Scholar
  19. 19.
    Shuin, T, Kondo, K, Torigoe, S,  et al. 1994Frequent somatic mutations and loss of heterozygosity of the von Hippel–Lindau tumor suppressor gene in primary human renal cell carcinomasCancer Res5428522855PubMedGoogle Scholar
  20. 20.
    Covello, KL, Simon, MC 2004HIFs, hypoxia, and vascular developmentCurr Top Dev Biol623754PubMedGoogle Scholar
  21. 21.
    Schofield, CJ, Ratcliffe, PJ 2005Signalling hypoxia by HIF hydroxylasesBiochem Biophys Res Commun338617626CrossRefPubMedGoogle Scholar
  22. 22.
    Shuin, T, Yamazaki, I, Tamura, K,  et al. 2004Recent advances in ideas on the molecular pathology and clinical aspects of von Hippel–Lindau diseaseInt J Clin Oncol9283287CrossRefPubMedGoogle Scholar
  23. 23.
    Brieger, J, Weidt, EJ, Schirmacher, P,  et al. 1999Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumorsJ Mol Med77505510CrossRefPubMedGoogle Scholar
  24. 24.
    Okuda, H, Saitoh, K, Hirai, S,  et al. 2001The von Hippel–Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase CJ Biol Chem2764361143617CrossRefPubMedGoogle Scholar
  25. 25.
    Danilkovitch-Miagkova, A, Zbar, B 2002Dysregulation of Met receptor tyrosine kinase activity in invasive tumorsJ Clin Invest109863867CrossRefPubMedGoogle Scholar
  26. 26.
    Natali, PG, Prat, M, Nicotra, MR,  et al. 1996Overexpression of the met/HGF receptor in renal cell carcinomasInt J Cancer69212217CrossRefPubMedGoogle Scholar
  27. 27.
    Nakamura, T, Kanda, S, Yamamoto, K,  et al. 2001Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activationOncogene2076107623PubMedGoogle Scholar
  28. 28.
    Zhang, YW, Su, Y, Volpert, OV,  et al. 2003Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulationProc Natl Acad Sci U S A1001271812723PubMedGoogle Scholar
  29. 29.
    Miyata, Y, Ashida, S, Nakamura, T,  et al. 2003Overexpression of hepatocyte growth factor receptor in renal carcinoma cells indirectly stimulates tumor growth in vivoBiochem Biophys Res Commun302892897CrossRefPubMedGoogle Scholar
  30. 30.
    Kuhnen, C, Muehlberger, T, Honsel, M,  et al. 2003Impact of c-Met expression on angiogenesis in soft tissue sarcomas: correlation to microvessel-densityJ Cancer Res Clin Oncol129415422CrossRefPubMedGoogle Scholar
  31. 31.
    Strohmeyer, D, Strauss, F, Rossing, C,  et al. 2004Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinomaAnticancer Res2417971804PubMedGoogle Scholar
  32. 32.
    Corso, S, Comoglio, PM, Giordano, S 2005Cancer therapy: can the challenge be MET?Trends Mol Med11284292CrossRefPubMedGoogle Scholar
  33. 33.
    Jacobs, SC, Lawson, RK 1980Mitogenic factor in human prostate extractsUrology16488491CrossRefPubMedGoogle Scholar
  34. 34.
    Story, MT, Esch, F, Shimasaki, S,  et al. 1987Amino-terminal sequence of a large form of basic fibroblast growth factor isolated from human benign prostatic hyperplastic tissueBiochem Biophys Res Commun142702709CrossRefPubMedGoogle Scholar
  35. 35.
    Crabb, JW, Armes, LG, Carr, SA,  et al. 1986Complete primary structure of prostatropin, a prostate epithelial cell growth factorBiochemistry2549884993CrossRefPubMedGoogle Scholar
  36. 36.
    Ornitz, DM, Itoh, N 2001Fibroblast growth factorsGenome Biol23005.13005.12CrossRefGoogle Scholar
  37. 37.
    Klint, P, Claesson-Welsh, L 1999Signal transduction by fibroblast growth factor receptorsFront Biosci4D165D177PubMedGoogle Scholar
  38. 38.
    Eswarakumar, VP, Lax, I, Schlessinger, J 2005Cellular signaling by fibroblast growth factor receptorsCytokine Growth Factor Rev16139149CrossRefPubMedGoogle Scholar
  39. 39.
    Beer, HD, Vindevoghel, L, Gait, MJ,  et al. 2000Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs that is preferentially expressed in the skin and the brainJ Biol Chem2751609116097CrossRefPubMedGoogle Scholar
  40. 40.
    Nakamura, T, Mochizuki, Y, Kanetake, H,  et al. 2001Signals via FGF receptor 2 regulate migration of endothelial cellsBiochem Biophys Res Commun289801806PubMedGoogle Scholar
  41. 41.
    Giri, D, Ropiquet, F, Ittmann, M 1999Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancerClin Cancer Res510631071PubMedGoogle Scholar
  42. 42.
    Kwabi-Addo, B, Ropiquet, F, Giri, D,  et al. 2001Alternative splicing of fibroblast growth factor receptors in human prostate cancerProstate46163172CrossRefPubMedGoogle Scholar
  43. 43.
    Wang, J, Stockton, DW, Ittmann, M 2004The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progressionClin Cancer Res1061696178PubMedGoogle Scholar
  44. 44.
    Ropiquet, F, Giri, D, Kwabi-Addo, B,  et al. 2000Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancerCancer Res6042454250PubMedGoogle Scholar
  45. 45.
    Polnaszek, N, Kwabi-Addo, B, Wang, J, Ittmann, M 2004FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasiaProstate20041824Google Scholar
  46. 46.
    Dorkin, TJ, Robinson, MC, Marsh, C,  et al. 1999a-FGF immunoreactivity in prostate cancer and its co-localization with b-FGF and FGF-8J Pathol189564569CrossRefPubMedGoogle Scholar
  47. 47.
    Leung, HY, Dickson, C, Robson, CN,  et al. 1996Over-expression of fibroblast growth factor-8 in human prostate cancerOncogene1218331835PubMedGoogle Scholar
  48. 48.
    Dorkin, TJ, Robinson, MC, Marsh, C,  et al. 1999FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent diseaseOncogene1827552761CrossRefPubMedGoogle Scholar
  49. 49.
    Sugamoto, T, Tanji, N, Sato, K,  et al. 2001The expression of basic fibroblast growth factor and vascular endothelial growth factor in prostatic adenocarcinoma: correlation with neovascularizationAnticancer Res217788PubMedGoogle Scholar
  50. 50.
    Joseph, IB, Isaacs, JT 1997Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancersCancer Res5710541057PubMedGoogle Scholar
  51. 51.
    Colombel, M, Filleur, S, Fournier, P,  et al. 2005Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostateCancer Res65300308PubMedGoogle Scholar
  52. 52.
    Doll, JA, Reiher, FK, Crawford, SE,  et al. 2001Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostateProstate49293305CrossRefPubMedGoogle Scholar
  53. 53.
    Shih, SJ, Dall'Era, MA, Westphal, JR,  et al. 2003Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissueProstate Cancer Prostatic Dis6131137CrossRefPubMedGoogle Scholar
  54. 54.
    Foley, SJ, Bailey, DM 2000Microvessel density in prostatic hyperplasiaBJU Int857073CrossRefPubMedGoogle Scholar
  55. 55.
    Bochner, BH, Cote, RJ, Weidner, N,  et al. 1995Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosisJ Natl Cancer Inst8716031612PubMedGoogle Scholar
  56. 56.
    Philp, EA, Stephenson, TJ, Reed, MW 1996Prognostic significance of angiogenesis in transitional cell carcinoma of the human urinary bladderBr J Urol77352357PubMedGoogle Scholar
  57. 57.
    Dinney, CP, Babkowski, RC, Antelo, M,  et al. 1998Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladderJ Urol16012851290PubMedGoogle Scholar
  58. 58.
    Sagol, O, Yorukoglu, K, Sis, B,  et al. 2001Does angiogenesis predict recurrence in superficial transitional cell carcinoma of the bladder?Urology57895899CrossRefPubMedGoogle Scholar
  59. 59.
    O'Brien, T, Cranston, D, Fuggle, S,  et al. 1995Different angiogenic pathways characterize superficial and invasive bladder cancerCancer Res55510513PubMedGoogle Scholar
  60. 60.
    Chow, NH, Liu, HS, Chan, SH,  et al. 1999Expression of vascular endothelial growth factor in primary superficial bladder cancerAnticancer Res1945934597PubMedGoogle Scholar
  61. 61.
    Prives, C, Hall, PA 1999The p53 pathwayJ Pathol187112126CrossRefPubMedGoogle Scholar
  62. 62.
    Dameron, KM, Volpert, OV, Tainsky, MA,  et al. 1994Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1Science26515821584PubMedGoogle Scholar
  63. 63.
    Nishimori, H, Shiratsuchi, T, Urano, T,  et al. 1997A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesisOncogene1521452150CrossRefPubMedGoogle Scholar
  64. 64.
    Sherif, ZA, Nakai, S, Pirollo, KF,  et al. 2001Downmodulation of bFGF-binding protein expression following restoration of p53 functionCancer Gene Ther8771782CrossRefPubMedGoogle Scholar
  65. 65.
    Powers, CJ, McLeskey, SW, Wellstein, A 2000Fibroblast growth factors, their receptors and signalingEndocr Relat Cancer7165197CrossRefPubMedGoogle Scholar
  66. 66.
    Ravi, R, Mookerjee, B, Bhujwalla, ZM,  et al. 2000Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alphaGenes Dev143444PubMedGoogle Scholar
  67. 67.
    Zhang, L, Yu, D, Hu, M,  et al. 2000Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expressionCancer Res6036553661PubMedGoogle Scholar
  68. 68.
    Malats, N, Bustos, A, Nascimento, CM,  et al. 2005P53 as a prognostic marker for bladder cancer: a meta-analysis and reviewLancet Oncol6678686PubMedGoogle Scholar
  69. 69.
    Grossfeld, GD, Ginsberg, DA, Stein, JP,  et al. 1997Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progressionJ Natl Cancer Inst89219227CrossRefPubMedGoogle Scholar
  70. 70.
    Theodoropoulos, VE, Lazaris, AC, Sofras, F,  et al. 2004Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancerEur Urol46200208CrossRefPubMedGoogle Scholar
  71. 71.
    Greenblatt, MS, Bennett, WP, Hollstein, M,  et al. 1994Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesisCancer Res5448554878PubMedGoogle Scholar
  72. 72.
    Moll, UM, Slade, N 2004p63 and p73: roles in development and tumor formationMol Cancer Res2371386PubMedGoogle Scholar
  73. 73.
    Akiyama, S, Furukawa, T, Sumizawa, T,  et al. 2004The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progressionCancer Sci95851857CrossRefPubMedGoogle Scholar
  74. 74.
    Ishikawa, F, Miyazono, K, Hellman, U,  et al. 1989Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factorNature (Lond)338557562Google Scholar
  75. 75.
    Brown, NS, Jones, A, Fujiyama, C,  et al. 2000Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factorsCancer Res6062986302PubMedGoogle Scholar
  76. 76.
    O'Brien, T, Cranston, D, Fuggle, S, Bicknell, R, Harris, AL 1995Different angiogenic pathways characterize superficial and invasive bladder cancerCancer Res55510513PubMedGoogle Scholar
  77. 77.
    O'Brien, TS, Fox, SB, Dickinson, AJ,  et al. 1996Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancersCancer Res5647994804PubMedGoogle Scholar
  78. 78.
    Arima, J, Imazono, Y, Takebayashi, Y,  et al. 2000Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladderCancer (Phila)8811311138Google Scholar
  79. 79.
    Tammela, T, Petrova, TV, Alitalo, K 2005Molecular lymphangiogenesis: new playersTrends Cell Biol15434441CrossRefPubMedGoogle Scholar
  80. 80.
    Cross, MJ, Dixelius, J, Matsumoto, T,  et al. 2003VEGF-receptor signal transductionTrends Biochem Sci28488494CrossRefPubMedGoogle Scholar
  81. 81.
    Makinen, T, Veikkola, T, Mustjoki, S,  et al. 2001Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3EMBO J2047624773CrossRefPubMedGoogle Scholar
  82. 82.
    Cao, Y, Linden, P, Farnebo, J,  et al. 1998Vascular endothelial growth factor C induces angiogenesis in vivoProc Natl Acad Sci U S A951438914394PubMedGoogle Scholar
  83. 83.
    Marconcini, L, Marchio, S, Morbidelli, L,  et al. 1999c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitroProc Natl Acad Sci U S A9696719676CrossRefPubMedGoogle Scholar
  84. 84.
    Ward, NL, Dumont, DJ 2002The angiopoietins and Tie2/Tek: adding to the complexity of cardiovascular developmentSemin Cell Dev Biol131927CrossRefPubMedGoogle Scholar
  85. 85.
    Gale, NW, Thurston, G, Hackett, SF,  et al. 2002Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1Dev Cell3411423CrossRefPubMedGoogle Scholar
  86. 86.
    Cao, Y 2005Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasisNat Rev Cancer5735743CrossRefPubMedGoogle Scholar
  87. 87.
    Gunningham, SP, Currie, MJ, Han, C,  et al. 2001Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel–Lindau gene and hypoxiaCancer Res6132063211PubMedGoogle Scholar
  88. 88.
    Tsuchiya, N, Sato, K, Akao, T,  et al. 2001Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinomaTohoku J Exp Med195101113CrossRefPubMedGoogle Scholar
  89. 89.
    Tsurusaki, T, Kanda, S, Sakai, H,  et al. 1999Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasisBr J Cancer80309313CrossRefPubMedGoogle Scholar
  90. 90.
    Stearns, ME, Wang, M, Hu, Y,  et al. 2004Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasisLab Invest84785795CrossRefPubMedGoogle Scholar
  91. 91.
    Li, J, Wang, E, Rinaldo, F,  et al. 2005Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathwayOncogene2455105520PubMedGoogle Scholar
  92. 92.
    Suzuki, K, Morita, T, Tokue, A 2005Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladderInt J Urol12152158PubMedGoogle Scholar
  93. 93.
    Miyata, Y, Kanda, S, Ohba, K,  et al. 2006Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implication and regulation by vascular endothelial growth factors-A, -C, and -DClin Cancer Res12800806CrossRefPubMedGoogle Scholar
  94. 94.
    Lind, AJ, Wikstrom, P, Granfors, T,  et al. 2005Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancerProstate62394399PubMedGoogle Scholar
  95. 95.
    Oka, N, Yamamoto, Y, Takahashi, M,  et al. 2005Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancerBJU Int95660663CrossRefPubMedGoogle Scholar
  96. 96.
    Concolino, G, Di Silverio, F, Marocchi, A,  et al. 1979Renal cancer steroid receptors: biochemical basis for endocrine therapyEur Urol59093PubMedGoogle Scholar
  97. 97.
    Gross, J, Azizkhan, RG, Biswas, C,  et al. 1981Inhibition of tumor growth, vascularization, and collagenolysis in the rabbit cornea by medroxyprogesteroneProc Natl Acad Sci U S A7811761180PubMedGoogle Scholar
  98. 98.
    Gagliardi, A, Collins, DC 1993Inhibition of angiogenesis by antiestrogensCancer Res53533535PubMedGoogle Scholar
  99. 99.
    Atzpodien, J, Kirchner, H, Illiger, HJ,  et al. 2001IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trialBr J Cancer8511301136CrossRefPubMedGoogle Scholar
  100. 100.
    Lindner, DJ 2002Interferons as antiangiogenic agentsCurr Oncol Rep4510514PubMedGoogle Scholar
  101. 101.
    Dinney, CP, Bielenberg, DR, Perrotte, P,  et al. 1998Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administrationCancer Res58808814PubMedGoogle Scholar
  102. 102.
    von Marschall, Z, Scholz, A, Cramer, T,  et al. 2003Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesisJ Natl Cancer Inst95437448PubMedGoogle Scholar
  103. 103.
    Angiolillo, AL, Sgadari, C, Taub, DD,  et al. 1995Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivoJ Exp Med182155162CrossRefPubMedGoogle Scholar
  104. 104.
    Raffaella, R, Gioia, D, De Andrea, M,  et al. 2004The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cellsExp Cell Res293331345CrossRefPubMedGoogle Scholar
  105. 105.
    Schwartz, EL, Wan, E, Wang, FS,  et al. 1998Regulation of expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in human colon carcinoma cellsCancer Res5815511557PubMedGoogle Scholar
  106. 106.
    Cozzolino, F, Torcia, M, Lucibello, M,  et al. 1993Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growthJ Clin Invest9125042512PubMedGoogle Scholar
  107. 107.
    Coppin, C, Porzsolt, F, Awa, A,  et al. 2004Immunotherapy for advanced renal cell cancerCochrane Database Syst Rev1CD001425Google Scholar
  108. 108.
    Atzpodien, J, Kirchner, H, Jonas, U,  et al. 2004Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)J Clin Oncol2211881194CrossRefPubMedGoogle Scholar
  109. 109.
    Négrier, S, Escudier, B, Lasset, C,  et al. 1998Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma: Groupe Francais d'ImmunotherapieN Engl J Med33812721278PubMedGoogle Scholar
  110. 110.
    Négrier, S, Caty, A, Lesimple, T,  et al. 2000Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil: Groupe Francais d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le CancerJ Clin Oncol1840094015PubMedGoogle Scholar
  111. 111.
    Négrier, S 2004Better survival with interleukin-2-based regimens? Possibly only in highly selected patientsJ Clin Oncol2211741176PubMedGoogle Scholar
  112. 112.
    Voest, EE, Kenyon, BM, O'Reilly, MS,  et al. 1995Inhibition of angiogenesis in vivo by interleukin 12J Natl Cancer Inst87581586PubMedGoogle Scholar
  113. 113.
    Sgadari, C, Angiolillo, AL, Tosato, G 1996Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10Blood8738773882PubMedGoogle Scholar
  114. 114.
    Motzer, RJ, Rakhit, A, Thompson, JA,  et al. 2001Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinomaJ Interferon Cytokine Res21257263CrossRefPubMedGoogle Scholar
  115. 115.
    Gollob, JA, Veenstra, KG, Parker, RA,  et al. 2003Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinomaJ Clin Oncol2125642573CrossRefPubMedGoogle Scholar
  116. 116.
    Alatrash, G, Hutson, TE, Molto, L,  et al. 2004Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanomaJ Clin Oncol2228912900CrossRefPubMedGoogle Scholar
  117. 117.
    Kondo, T, Ito, F, Nakazawa, H,  et al. 2004High expression of chemokine gene as a favorable prognostic factor in renal cell carcinomaJ Urol17121712175CrossRefPubMedGoogle Scholar
  118. 118.
    Stein, CA 1993Suramin: a novel antineoplastic agent with multiple potential mechanisms of actionCancer Res5322392248PubMedGoogle Scholar
  119. 119.
    Motzer, RJ, Nanus, DM, O'Moore, P,  et al. 1992Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expressionCancer Res5257755779PubMedGoogle Scholar
  120. 120.
    Dreicer, R, Smith, DC, Williams, RD,  et al. 1999Phase II trial of suramin in patients with metastatic renal cell carcinomaInvest New Drugs17183186CrossRefPubMedGoogle Scholar
  121. 121.
    Schroder, LE, Lew, D, Flanigan, RC,  et al. 2001Phase II evaluation of suramin in advanced renal cell carcinoma. A Southwest Oncology Group studyUrol Oncol6145148PubMedGoogle Scholar
  122. 122.
    Myers, C, Cooper, M, Stein, C,  et al. 1992Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancerJ Clin Oncol10881889PubMedGoogle Scholar
  123. 123.
    Lara, PN,Jr, Twardowski, P, Quinn, DI 2004Angiogenesis-targeted therapies in prostate cancerClin Prostate Cancer3165173PubMedGoogle Scholar
  124. 124.
    Small, EJ, McMillan, A, Meyer, M,  et al. 2001Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survivalJ Clin Oncol1913041311PubMedGoogle Scholar
  125. 125.
    Garcia-Schurmann, JM, Schulze, H, Haupt, G,  et al. 1999Suramin treatment in hormone- and chemotherapy-refractory prostate cancerUrology53535541PubMedGoogle Scholar
  126. 126.
    Falcone, A, Antonuzzo, A, Danesi, R,  et al. 1999Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinomaCancer (Phila)86470476Google Scholar
  127. 127.
    Small, EJ, Meyer, M, Marshall, ME,  et al. 2000Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisoneJ Clin Oncol1814401450PubMedGoogle Scholar
  128. 128.
    Calvo, E, Cortes, J, Rodriguez, J,  et al. 2001Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma: a multicenter Phase II studyCancer (Phila)9224352443Google Scholar
  129. 129.
    Small, EJ, Halabi, S, Ratain, MJ,  et al. 2002Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480J Clin Oncol2033693375CrossRefPubMedGoogle Scholar
  130. 130.
    Vogelzang, NJ, Karrison, T, Stadler, WM,  et al. 2004A Phase II trial of suramin monthly ×3 for hormone-refractory prostate carcinomaCancer (Phila)1006571Google Scholar
  131. 131.
    Uchio, EM, Linehan, WM, Figg, WD,  et al. 2003A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladderJ Urol169357360CrossRefPubMedGoogle Scholar
  132. 132.
    Ord, JJ, Streeter, E, Jones, A,  et al. 2005Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinomaBr J Cancer9221402147CrossRefPubMedGoogle Scholar
  133. 133.
    Ingber, D, Fujita, T, Kishimoto, S,  et al. 1990Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growthNature (Lond)348555557Google Scholar
  134. 134.
    Hori, A, Ikeyama, S, Sudo, K 1994Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cellsBiochem Biophys Res Commun20410671073CrossRefPubMedGoogle Scholar
  135. 135.
    Abe, J, Zhou, W, Takuwa, N,  et al. 1994A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cellsCancer Res5434073412PubMedGoogle Scholar
  136. 136.
    Sin, N, Meng, L, Wang, MQ,  et al. 1997The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2Proc Natl Acad Sci U S A9460996103CrossRefPubMedGoogle Scholar
  137. 137.
    Yamaoka, M, Yamamoto, T, Ikeyama, S,  et al. 1993Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell linesCancer Res5352335236PubMedGoogle Scholar
  138. 138.
    Yanase, T, Tamura, M, Fujita, K,  et al. 1993Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivoCancer Res5325662570PubMedGoogle Scholar
  139. 139.
    Morita, T, Shinohara, N, Tokue, A 1994Antitumour effect of a synthetic analogue of fumagillin on murine renal carcinomaBr J Urol74416421PubMedGoogle Scholar
  140. 140.
    Bernsen, HJ, Rijken, PF, Peters, H,  et al. 1998The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude miceJ Neuro-oncol385157CrossRefGoogle Scholar
  141. 141.
    Morales, C, Zurita, M, Vaquero, J 2002Antitumor effect of TNP-470 is not associated to decrease of angiogenesis in an experimental malignant neuroectodermic tumorJ Neuro-oncol58131136CrossRefGoogle Scholar
  142. 142.
    Huang, J, Frischer, JS, New, T,  et al. 2004TNP-470 promotes initial vascular sprouting in xenograft tumorsMol Cancer Ther3335343PubMedGoogle Scholar
  143. 143.
    Stadler, WM, Kuzel, T, Shapiro, C,  et al. 1999Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinomaJ Clin Oncol1725412545PubMedGoogle Scholar
  144. 144.
    Logothetis, CJ, Wu, KK, Finn, LD,  et al. 2001Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancerClin Cancer Res711981203PubMedGoogle Scholar
  145. 145.
    Satchi-Fainaro, R, Puder, M, Davies, JW,  et al. 2004Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470Nat Med10255261CrossRefPubMedGoogle Scholar
  146. 146.
    Moreira, AL, Sampaio, EP, Zmuidzinas, A,  et al. 1993Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradationJ Exp Med17716751680CrossRefPubMedGoogle Scholar
  147. 147.
    Keifer, JA, Guttridge, DC, Ashburner, BP,  et al. 2001Inhibition of NF-kappa B activity by thalidomide through suppression of I-kappa-B kinase activityJ Biol Chem2762238222387CrossRefPubMedGoogle Scholar
  148. 148.
    Fujita, J, Mestre, JR, Zeldis, JB,  et al. 2001Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2Clin Cancer Res733493355PubMedGoogle Scholar
  149. 149.
    Stebbing, J, Benson, C, Eisen, T,  et al. 2001The treatment of advanced renal cell cancer with high-dose oral thalidomideBr J Cancer85953958CrossRefPubMedGoogle Scholar
  150. 150.
    Motzer, RJ, Berg, W, Ginsberg, M,  et al. 2002Phase II trial of thalidomide for patients with advanced renal cell carcinomaJ Clin Oncol20302306PubMedGoogle Scholar
  151. 151.
    Escudier, B, Lassau, N, Couanet, D,  et al. 2002Phase II trial of thalidomide in renal-cell carcinomaAnn Oncol1310291035CrossRefPubMedGoogle Scholar
  152. 152.
    Daliani, DD, Papandreou, CN, Thall, PF,  et al. 2002A pilot study of thalidomide in patients with progressive metastatic renal cell carcinomaCancer (Phila)95758765Google Scholar
  153. 153.
    Desai, AA, Vogelzang, NJ, Rini, BI,  et al. 2002A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinomaCancer (Phila)9516291636Google Scholar
  154. 154.
    Nathan, PD, Gore, ME, Eisen, TG 2002Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinomaJ Clin Oncol2014291430PubMedGoogle Scholar
  155. 155.
    Hernberg M, Virkkunen P, Bono P, et al. Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 21:3770–3776Google Scholar
  156. 156.
    Dixon, SC, Kruger, EA, Bauer, KS,  et al. 1999Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cellsCancer Chemother Pharmacol43S78S84PubMedGoogle Scholar
  157. 157.
    Figg, WD, Dahut, W, Duray, P,  et al. 2001A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancerClin Cancer Res718881893PubMedGoogle Scholar
  158. 158.
    Drake, MJ, Robson, W, Mehta, P,  et al. 2003An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancerBr J Cancer88822827CrossRefPubMedGoogle Scholar
  159. 159.
    Figg, WD, Arlen, P, Gulley, J,  et al. 2001A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancerSemin Oncol 2846266Google Scholar
  160. 160.
    Horne, MK,III, Figg, WD, Arlen, P,  et al. 2003Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancerPharmacotherapy23315318PubMedGoogle Scholar
  161. 161.
    Dahut, WL, Gulley, JL, Arlen, PM,  et al. 2004Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancerJ Clin Oncol2225322539CrossRefPubMedGoogle Scholar
  162. 162.
    Chang, DZ, Lomazow, W, Joy Somberg, C,  et al. 2004Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccinesHematology9207215CrossRefPubMedGoogle Scholar
  163. 163.
    Small, EJ, Reese, DM, Um, B,  et al. 1999Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factorClin Cancer Res517381744PubMedGoogle Scholar
  164. 164.
    Eubank, TD, Roberts, R, Galloway, M,  et al. 2004GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in miceImmunity21831842CrossRefPubMedGoogle Scholar
  165. 165.
    Dreicer, R, Klein, EA, Elson, P,  et al. 2005Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancerUrol Oncol238286PubMedGoogle Scholar
  166. 166.
    Bartlett, JB, Tozer, A, Stirling, D,  et al. 2005Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomideBr J Cancer93613619CrossRefPubMedGoogle Scholar
  167. 167.
    Falardeau, P, Champagne, P, Poyet, P,  et al. 2001Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trialsSemin Oncol28620625CrossRefPubMedGoogle Scholar
  168. 168.
    Batist, G, Patenaude, F, Champagne, P,  et al. 2002Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levelsAnn Oncol1312591263CrossRefPubMedGoogle Scholar
  169. 169.
    Bukowski, RM 2003AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinomaExpert Opin Invest Drugs1214031411CrossRefGoogle Scholar
  170. 170.
    Armstrong, LC, Bornstein, P 2003Thrombospondins 1 and 2 function as inhibitors of angiogenesisMatrix Biol226371CrossRefPubMedGoogle Scholar
  171. 171.
    Sid, B, Sartelet, H, Bellon, G,  et al. 2004Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growthCrit Rev Oncol Hematol49245258PubMedGoogle Scholar
  172. 172.
    Kanda, S, Shono, T, Tomasini-Johansson, B,  et al. 1999Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesisExp Cell Res252262272CrossRefPubMedGoogle Scholar
  173. 173.
    Miyata, Y, Koga, S, Takehara, K,  et al. 2003Expression of thrombospondin-derived 4N1K peptide-containing proteins in renal cell carcinoma tissues is associated with a decrease in tumor growth and angiogenesisClin Cancer Res917341740PubMedGoogle Scholar
  174. 174.
    Lawler, J, Detmar, M 2004Tumor progression: the effects of thrombospondin-1 and -2Int J Biochem Cell Biol3610381045CrossRefPubMedGoogle Scholar
  175. 175.
    Haviv, F, Bradley, MF, Kalvin, DM,  et al. 2005Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activitiesJ Med Chem4828382846CrossRefPubMedGoogle Scholar
  176. 176.
    Hoekstra, R, de Vos, FY, Eskens, FA,  et al. 2005Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancerJ Clin Oncol2351885197PubMedGoogle Scholar
  177. 177.
    Simmons, DL, Botting, RM, Hla, T 2004Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibitionPharmacol Rev56387437CrossRefPubMedGoogle Scholar
  178. 178.
    Miyata, Y, Koga, S, Kanda, S,  et al. 2003Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survivalClin Cancer Res917411749PubMedGoogle Scholar
  179. 179.
    Wang, W, Bergh, A, Damber, JE 2005Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancerClin Cancer Res1132503256PubMedGoogle Scholar
  180. 180.
    Shirahama, T, Arima, J, Akiba, S,  et al. 2001Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladderCancer (Phila)92188193Google Scholar
  181. 181.
    Pruthi, RS, Derksen, JE, Moore, D 2004A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomyBJU Int93275278PubMedGoogle Scholar
  182. 182.
    Rini, BI, Weinberg, V, Dunlap, S,  et al. 2006Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinomaCancer (Phila)106566575Google Scholar
  183. 183.
    Okajima, E, Denda, A, Ozono, S,  et al. 1998Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamineCancer Res5830283031PubMedGoogle Scholar
  184. 184.
    Mabjeesh, NJ, Escuin, D, LaVallee, TM,  et al. 20032ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIFCancer Cell3363375CrossRefPubMedGoogle Scholar
  185. 185.
    Sweeney, C, Liu, G, Yiannoutsos, C,  et al. 2005A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancerClin Cancer Res1166256633CrossRefPubMedGoogle Scholar
  186. 186.
    Kohn, EC, Alessandro, R, Spoonster, J,  et al. 1995Angiogenesis: role of calcium-mediated signal transductionProc Natl Acad Sci U S A9213071311PubMedGoogle Scholar
  187. 187.
    Kohn, EC, Figg, WD, Sarosy, GA,  et al. 1997Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulationsJ Clin Oncol1519851993PubMedGoogle Scholar
  188. 188.
    Bauer, KS, Figg, WD, Hamilton, JM,  et al. 1999A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancerClin Cancer Res523242329PubMedGoogle Scholar
  189. 189.
    Dutcher, JP, Leon, L, Manola, J,  et al. 2005Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapyCancer (Phila)10423922399Google Scholar
  190. 190.
    Stadler, WM, Rosner, G, Small, E,  et al. 2005Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma – CALGB 69901J Clin Oncol2337263732PubMedGoogle Scholar
  191. 191.
    Patstone, G, Maher, P 1996Copper and calcium binding motifs in the extracellular domains of fibroblast growth factor receptorsJ Biol Chem27133433346PubMedGoogle Scholar
  192. 192.
    Sen, CK, Khanna, S, Venojarvi, M,  et al. 2002Copper-induced vascular endothelial growth factor expression and wound healingAm J Physiol Heart Circ Physiol282H1821H1827PubMedGoogle Scholar
  193. 193.
    Sen, CK, Goodman, VL, Brewer, GJ, Merajver, SD 2004Copper deficiency as an anti-cancer strategyEndocr Relat Cancer11255263Google Scholar
  194. 194.
    Redman, BG, Esper, P, Pan, Q,  et al. 2003Phase II trial of tetrathiomolybdate in patients with advanced kidney cancerClin Cancer Res916661672PubMedGoogle Scholar
  195. 195.
    Tulpule, A, Espina, BM, Cabriales, S,  et al. 2065IM-862 nasal solution is an active antiangiogenic agent in the treatment of AIDS-related Kaposi's sarcomaProc Am Soc Clin Oncol18535a(abstract)Google Scholar
  196. 196.
    Ferrario, A, von Tiehl, KF, Rucker, N,  et al. 2000Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinomaCancer Res6040664069PubMedGoogle Scholar
  197. 197.
    Deplanque, G, Madhusudan, S, Jones, PH,  et al. 2004Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinomaBr J Cancer9116451650PubMedGoogle Scholar
  198. 198.
    Deshayes, F, Nahmias, C 2005Angiotensin receptors: a new role in cancer?Trends Endocrinol Metab16293299PubMedGoogle Scholar
  199. 199.
    Uemura, H, Hasumi, H, Kawahara, T,  et al. 2005Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancerInt J Clin Oncol10405410CrossRefPubMedGoogle Scholar
  200. 200.
    Barnes, CJ, Kumar, R 2003Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targetsCancer Metastasis Rev22301307CrossRefPubMedGoogle Scholar
  201. 201.
    Dreux AC, Lamb DJ, Modjtahedi H, et al. (2006) The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. Atherosclerosis (in press)Google Scholar
  202. 202.
    van Cruijsen, H, Giaccone, G, Hoekman, K 2005Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategiesInt J Cancer117883888CrossRefPubMedGoogle Scholar
  203. 203.
    Mydlo, JH, Michaeli, J, Cordon-Cardo, C,  et al. 1989Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissueCancer Res4934073411PubMedGoogle Scholar
  204. 204.
    Morris, GL, Dodd, JG 1990Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell linesJ Urol14312721274PubMedGoogle Scholar
  205. 205.
    Messing, EM 1990Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinomaCancer Res5025302537PubMedGoogle Scholar
  206. 206.
    Stumm, G, Eberwein, S, Rostock-Wolf, S,  et al. 1996Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasisInt J Cancer691722CrossRefPubMedGoogle Scholar
  207. 207.
    Signoretti, S, Montironi, R, Manola, J,  et al. 2000Her-2-neu expression and progression toward androgen independence in human prostate cancerJ Natl Cancer Inst9219181925CrossRefPubMedGoogle Scholar
  208. 208.
    Kruger, S, Weitsch, G, Buttner, H,  et al. 2002HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implicationsInt J Cancer102514518PubMedGoogle Scholar
  209. 209.
    Motzer, RJ, Amato, R, Todd, M,  et al. 2003Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinomaInvest New Drugs2199101CrossRefPubMedGoogle Scholar
  210. 210.
    Rowinsky, EK, Schwartz, GH, Gollob, JA,  et al. 2004Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancerJ Clin Oncol2230033015CrossRefPubMedGoogle Scholar
  211. 211.
    Dawson, NA, Guo, C, Zak, R,  et al. 2004A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinomaClin Cancer Res1078127819CrossRefPubMedGoogle Scholar
  212. 212.
    Jermann, M, Stahel, RA, Salzberg, M,  et al. 2006A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinomaCancer Chemother Pharmacol57533539CrossRefPubMedGoogle Scholar
  213. 213.
    Canil, CM, Moore, MJ, Winquist, E,  et al. 2005Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada–Clinical Trials GroupJ Clin Oncol23455460CrossRefPubMedGoogle Scholar
  214. 214.
    Hidalgo, M, Siu, LL, Nemunaitis, J,  et al. 2001Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesJ Clin Oncol1932673279PubMedGoogle Scholar
  215. 215.
    Beeram, M, Rowinsky, EK, Weiss, GR,  et al. 2004Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic and biological correlative study with FDG-PET imagingProc Am Soc Clin Oncol23207(abstract 3050)Google Scholar
  216. 216.
    Calvo, E, Tolcher, AW, Hammond, LA,  et al. 2004Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect studyClin Cancer Res1071127120CrossRefPubMedGoogle Scholar
  217. 217.
    Ziada, A, Barqawi, A, Glode, LM,  et al. 2004The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trialProstate60332337CrossRefPubMedGoogle Scholar
  218. 218.
    Presta, LG, Chen, H, O'Connor, SJ,  et al. 1997Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disordersCancer Res5745934599PubMedGoogle Scholar
  219. 219.
    Ferrara, N, Hillan, KJ, Novotny, W 2005Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapyBiochem Biophys Res Commun333328335CrossRefPubMedGoogle Scholar
  220. 220.
    Yang, JC, Haworth, L, Sherry, RM,  et al. 2003A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancerN Engl J Med349427434CrossRefPubMedGoogle Scholar
  221. 221.
    Elaraj, DM, White, DE, Steinberg, SM,  et al. 2004A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinomaJ Immunother27259264PubMedGoogle Scholar
  222. 222.
    Hainsworth, JD, Sosman, JA, Spigel, DR,  et al. 2005Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinibJ Clin Oncol2378897896PubMedGoogle Scholar
  223. 223.
    Rini, BI, Halabi, S, Taylor, J,  et al. 2004Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinomaClin Cancer Res1025842586CrossRefPubMedGoogle Scholar
  224. 224.
    Holash, J, Davis, S, Papadopoulos, N,  et al. 2002VEGF-Trap: a VEGF blocker with potent antitumor effectsProc Natl Acad Sci U S A991139311398CrossRefPubMedGoogle Scholar
  225. 225.
    Cursiefen, C, Cao, J, Chen, L,  et al. 2004Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survivalInvest Ophthalmol Vis Sci4526662673PubMedGoogle Scholar
  226. 226.
    Dupont, J, Schwartz, L, Koutcher, J,  et al. 2004Phase I and pharmacokinetic study of VEGF trap administerd subcutaneously to patients with advanced solid malignanciesProc Am Soc Clin Oncol23197(abstract 3009)Google Scholar
  227. 227.
    Kuenen, BC, Tabernero, J, Baselga, J,  et al. 2003Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcomaClin Cancer Res916481655PubMedGoogle Scholar
  228. 228.
    Lara, PN,Jr, Quinn, DI, Margolin, K,  et al. 2003SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibitionClin Cancer Res947724781PubMedGoogle Scholar
  229. 229.
    Stadler, WM, Cao, D, Vogelzang, NJ,  et al. 2004A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancerClin Cancer Res1033653370CrossRefPubMedGoogle Scholar
  230. 230.
    Stadler, WM 2005Targeted agents for the treatment of advanced renal cell carcinomaCancer (Phila)10423232333Google Scholar
  231. 231.
    Rugo, HS, Herbst, RS, Liu, G,  et al. 2005Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical resultsJ Clin Oncol2354745483CrossRefPubMedGoogle Scholar
  232. 232.
    Motzer, RJ, Dror Michaelson, M, Redman, BG,  et al. 2006Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinomaJ Clin Oncol241624CrossRefPubMedGoogle Scholar
  233. 233.
    Holden, SN, Eckhardt, SG, Basser, R,  et al. 2005Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumorsAnn Oncol1613911397CrossRefPubMedGoogle Scholar
  234. 234.
    Lyons, JF, Wilhelm, S, Hibner, B,  et al. 2001Discovery of a novel Raf kinase inhibitorEndocr Relat Cancer8219225CrossRefPubMedGoogle Scholar
  235. 235.
    Wilhelm, SM, Carter, C, Tang, L,  et al. 2004BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res6470997109CrossRefPubMedGoogle Scholar
  236. 236.
    Strumberg, D, Richly, H, Hilger, RA,  et al. 2005Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumorsJ Clin Oncol23965972PubMedGoogle Scholar
  237. 237.
    Awada, A, Hendlisz, A, Gil, T,  et al. 2005Phase I safety and pharmacokinetics of BAY 43–9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumoursBr J Cancer9218551861CrossRefPubMedGoogle Scholar
  238. 238.
    Moore, M, Hirte, HW, Siu, L,  et al. 2005Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43–9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumorsAnn Oncol1616881694CrossRefPubMedGoogle Scholar
  239. 239.
    Traxler, P, Allegrini, PR, Brandt, R,  et al. 2004AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activityCancer Res6449314941CrossRefPubMedGoogle Scholar
  240. 240.
    Young, RC 1998Metastatic renal-cell carcinoma: what causes occasional drastic regression?N Engl J Med33813051306PubMedGoogle Scholar
  241. 241.
    Gleave, ME, Elhilali, M, Fradet, Y,  et al. 1998Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology GroupN Engl J Med33812651271CrossRefPubMedGoogle Scholar
  242. 242.
    Oliver, RT, Nethersell, AB, Bottomley, JM 1989Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinomaBr J Urol63128131PubMedGoogle Scholar
  243. 243.
    Betsholtz, C, Johnsson, A, Heldin, CH,  et al. 1986Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suraminProc Natl Acad Sci U S A8364406444PubMedGoogle Scholar
  244. 244.
    Coffey, RJ,Jr, Leof, EB, Shipley, GD,  et al. 1987Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cellsJ Cell Physiol132143148CrossRefPubMedGoogle Scholar
  245. 245.
    Coughlin, SR, Barr, PJ, Cousens, LS,  et al. 1988Acidic and basic fibroblast growth factors stimulate tyrosine kinase activity in vivoJ Biol Chem263988993PubMedGoogle Scholar
  246. 246.
    Vaisman, N, Gospodarowicz, D, Neufeld, G 1990Characterization of the receptors for vascular endothelial growth factorJ Biol Chem2651946119466PubMedGoogle Scholar
  247. 247.
    Adams, JC, Furlong, RA, Watt, FM 1991Production of scatter factor by ndk, a strain of epithelial cells, and inhibition of scatter factor activity by suraminJ Cell Sci98385394PubMedGoogle Scholar
  248. 248.
    Pesenti, E, Sola, F, Mongelli, N,  et al. 1992Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activityBr J Cancer66367372PubMedGoogle Scholar
  249. 249.
    Kuenen, BC, Giaccone, G, Ruijter, R,  et al. 2005Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignanciesClin Cancer Res1162406246CrossRefPubMedGoogle Scholar
  250. 250.
    Roberts, JT 2005Chemotherapy for metastatic bladder cancerClin Oncol (R Coll Radiol)17514523Google Scholar
  251. 251.
    Logue, J, McBain, CA 2005Radiation therapy for muscle-invasive bladder cancer: treatment planning and deliveryClin Oncol (R Coll Radiol)17508513Google Scholar
  252. 252.
    Leonhardt, KO, Landes, RR 1963Oxygen tension of the urine and renal structures. Preliminary report of clinical findingsN Engl J Med269115121PubMedGoogle Scholar
  253. 253.
    Hockel, M, Vaupel, P 2001Tumor hypoxia: definitions and current clinical, biologic, and molecular aspectsJ Natl Cancer Inst93266276CrossRefPubMedGoogle Scholar
  254. 254.
    Leonhardt, KO, Landes, RR 1965Urinary oxygen pressure in renal parenchymal and vascular disease. Effects of breathing oxygenJAMA194345350CrossRefPubMedGoogle Scholar
  255. 255.
    Boehm, T, Folkman, J, Browder, T,  et al. 1997Antiangiogenic therapy of experimental cancer does not induce acquired drug resistanceNature (Lond)390404407Google Scholar
  256. 256.
    Casanovas, O, Hicklin, DJ, Bergers, G,  et al. 2005Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell8299309CrossRefPubMedGoogle Scholar
  257. 257.
    Hida, K, Hida, Y, Amin, DN,  et al. 2004Tumor-associated endothelial cells with cytogenetic abnormalitiesCancer Res6482498255CrossRefPubMedGoogle Scholar
  258. 258.
    Carmeliet, P 2005Angiogenesis in life, disease and medicineNature (Lond)438932936Google Scholar
  259. 259.
    Bergers, G, Song, S, Meyer-Morse, N,  et al. 2003Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsJ Clin Invest11112871295CrossRefPubMedGoogle Scholar
  260. 260.
    Suri, C, Jones, PF, Patan, S,  et al. 1996Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesisCell8711711180CrossRefPubMedGoogle Scholar
  261. 261.
    Maisonpierre, PC, Suri, C, Jones, PF,  et al. 1997Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesisScience2775560CrossRefPubMedGoogle Scholar
  262. 262.
    Kim, I, Kim, JH, Moon, SO,  et al. 2000Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathwayOncogene1945494552PubMedGoogle Scholar
  263. 263.
    Teichert-Kuliszewska, K, Maisonpierre, PC, Jones, N,  et al. 2001Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2Cardiovasc Res49659670CrossRefPubMedGoogle Scholar
  264. 264.
    Mochizuki, Y, Nakamura, T, Kanetake, H,  et al. 2002Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-FynJ Cell Sci115175183PubMedGoogle Scholar
  265. 265.
    Oliner, J, Min, H, Leal, J,  et al. 2004Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2Cancer Cell6507516CrossRefPubMedGoogle Scholar
  266. 266.
    Holmgren, L, O'Reilly, MS, Folkman, J 1995Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppressionNat Med1149153CrossRefPubMedGoogle Scholar
  267. 267.
    Miller, KD, Sweeney, CJ, Sledge, GW,Jr 2001Redefining the target: chemotherapeutics as antiangiogenicsJ Clin Oncol1911951206PubMedGoogle Scholar
  268. 268.
    Garcia-Barros, M, Paris, F, Cordon-Cardo, C,  et al. 2003Tumor response to radiotherapy regulated by endothelial cell apoptosisScience30011551159CrossRefPubMedGoogle Scholar

Copyright information

© The Japan Society of Clinical Oncology 2006

Authors and Affiliations

  • Shigeru Kanda
    • 1
  • Yasuyoshi Miyata
    • 2
  • Hiroshi Kanetake
    • 2
  1. 1.Department of Molecular Microbiology and Immunology, Division of Endothelial Cell BiologyNagasaki University Graduate School of Biomedical ScienceNagasakiJapan
  2. 2.Department of UrologyNagasaki University Graduate School of Biomedical ScienceNagasakiJapan
  3. 3.National Hospital OrganizationNagasaki HospitalNagasakiJapan

Personalised recommendations